WallStreetZenWallStreetZen

NASDAQ: NERV
Minerva Neurosciences Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for NERV

Based on 3 analysts offering 12 month price targets for Minerva Neurosciences Inc

Min Forecast
$7.00+45.53%
Avg Forecast
$10.33+114.82%
Max Forecast
$14.00+191.06%

Should I buy or sell NERV stock?

Based on 3 analysts offering ratings for Minerva Neurosciences Inc.

Buy
Strong Buy
1 analysts 33.33%
Buy
1 analysts 33.33%
Hold
1 analysts 33.33%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although NERV's forecast from analysts indicates a "Buy", our proven Zen Rating quant model rates NERV as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +5.11% per year. Learn More

Be the first to know when Wall Street analysts revise their NERV stock forecasts and price targets.

NERV stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-08-14
lockedlocked$00.00+00.00%2026-04-15
lockedlocked$00.00+00.00%2026-03-12

1 of 1

Forecast return on equity

Is NERV forecast to generate an efficient return?

Company
-14.38%
Industry
16.16%
Market
168.62%
NERV's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is NERV forecast to generate an efficient return on assets?

Company
32.27%
Industry
23.18%
NERV is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

NERV earnings per share forecast

What is NERV's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$1.92
Avg 2 year Forecast
-$0.53
Avg 3 year Forecast
-$0.68

NERV revenue forecast

What is NERV's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0
Avg 3 year Forecast
$13.0M

NERV vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
NERV$4.81$10.33+114.82%Buy
TARA$3.87$27.00+597.67%Strong Buy
CLLS$3.19$8.50+166.46%Strong Buy
RNA$13.62$25.00+83.55%Strong Buy
DTIL$8.45$36.67+333.93%Strong Buy
View Top Biotech Stocks

Minerva Neurosciences Stock Forecast FAQ

Is Minerva Neurosciences Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 3 Wall Street analysts covering (NASDAQ: NERV) stock is to Buy NERV stock.

Out of 3 analysts, 1 (33.33%) are recommending NERV as a Strong Buy, 1 (33.33%) are recommending NERV as a Buy, 1 (33.33%) are recommending NERV as a Hold, 0 (0%) are recommending NERV as a Sell, and 0 (0%) are recommending NERV as a Strong Sell.

If you're new to stock investing, here's how to buy Minerva Neurosciences stock.

What is NERV's earnings growth forecast for 2026-2028?

(NASDAQ: NERV) Minerva Neurosciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 10.5%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.33%.

Minerva Neurosciences's earnings in 2026 is -$395,169,043.On average, 5 Wall Street analysts forecast NERV's earnings for 2026 to be -$91,804,232, with the lowest NERV earnings forecast at -$167,049,610, and the highest NERV earnings forecast at -$10,026,987. On average, 5 Wall Street analysts forecast NERV's earnings for 2027 to be -$25,325,305, with the lowest NERV earnings forecast at -$44,452,977, and the highest NERV earnings forecast at -$4,512,144.

In 2028, NERV is forecast to generate -$32,339,422 in earnings, with the lowest earnings forecast at -$69,625,491 and the highest earnings forecast at $8,021,590.

What is NERV's revenue growth forecast for 2026-2028?

(NASDAQ: NERV) Minerva Neurosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.4%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.13%.

Minerva Neurosciences's revenue in 2026 is $0.On average, 5 Wall Street analysts forecast NERV's revenue for 2026 to be $0, with the lowest NERV revenue forecast at $0, and the highest NERV revenue forecast at $0. On average, 5 Wall Street analysts forecast NERV's revenue for 2027 to be $0, with the lowest NERV revenue forecast at $0, and the highest NERV revenue forecast at $0.

In 2028, NERV is forecast to generate $620,909,257 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $1,917,494,222.

What is NERV's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: NERV) forecast ROA is 32.27%, which is higher than the forecast US Biotechnology industry average of 23.18%.

What is NERV's Price Target?

According to 3 Wall Street analysts that have issued a 1 year NERV price target, the average NERV price target is $10.33, with the highest NERV stock price forecast at $14.00 and the lowest NERV stock price forecast at $7.00.

On average, Wall Street analysts predict that Minerva Neurosciences's share price could reach $10.33 by Aug 14, 2027. The average Minerva Neurosciences stock price prediction forecasts a potential upside of 114.82% from the current NERV share price of $4.81.

What is NERV's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: NERV) Minerva Neurosciences's current Earnings Per Share (EPS) is -$36.24. On average, analysts forecast that NERV's EPS will be -$1.92 for 2026, with the lowest EPS forecast at -$3.50, and the highest EPS forecast at -$0.21. On average, analysts forecast that NERV's EPS will be -$0.53 for 2027, with the lowest EPS forecast at -$0.93, and the highest EPS forecast at -$0.09. In 2028, NERV's EPS is forecast to hit -$0.68 (min: -$1.46, max: $0.17).

What is NERV's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: NERV) forecast ROE is -14.38%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.